儿童急性淋巴细胞白血病复发检测方式及其对生存的影响:北欧人群队列研究
该北欧人群队列研究纳入1992至2014年确诊并完成治疗的3262例儿童ALL患者,其中338例复发。复发检测在额外就诊与计划随访间均等分布,检测方式非总生存独立危险因素;停疗后5年内诊断1例亚临床复发需约1269次计划血检。基于OS数据,计划随访似无额外获益。
要点
- 复发的检测方式(额外就诊 vs 计划随访)不影响复发后总生存。
- 停疗后5年内诊断1例亚临床复发需约1269次计划血检,负担较高。
- 基于OS数据,完成治疗后计划随访似无额外获益,应据此调整随访策略。
核心结论
- 基于总生存数据,完成治疗后计划随访未显示额外获益,检测方式非复发后OS独立危险因素。
研究设计与样本
- 北欧人群为基础队列研究,纳入1992至2014年确诊并完成ALL方案治疗的3262例儿童患者,其中338例复发。
主要发现
- 症状持续时间非复发后OS独立危险因素。
- 停疗后5年内诊断1例亚临床复发需计划血检1269次(95%CI 902-1637)。
临床怎么用
- 可考虑减少完成治疗后以血检为主的计划随访,转向症状驱动监测。
- 与家庭沟通复发警示症状,确保出现症状时及时额外就诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapse constitutes the greatest threat to event-free survival after completion of treatment for childhood acute lymphoblastic leukaemia (ALL). However, evidence on optimal follow-up schedules is limited. The aims of the present population-based cohort study were to assess the value of current follow-up schedules after completion of Nordic Society of Paediatric Haematology and Oncology ALL protocol treatment and to estimate the impact of relapse detection mode on overall survival (OS). Among 3262 patients diagnosed between 1992 and 2014 and who completed treatment, 338 developed a relapse. Relapse detection was equally distributed between extra visits (50·8%) and scheduled follow-up visits (49·2%). All cases detected at an extra visit and 64·3% of cases detected at a scheduled visit presented with symptoms or objective findings. Neither the mode of detection {adjusted hazard ratio 0·95, [95% confidence interval (CI) 0·61-1·48] for scheduled visits} nor the duration of symptoms was an independent risk factor for OS after relapse. The estimated number of scheduled blood samples needed to diagnose one subclinical relapse during the first 5 years after treatment cessation was 1269 (95% CI 902-1637). In conclusion, based on OS data, scheduled visits after cessation of therapy seem to yield no extra benefit. These results should frame future follow-up strategies.
引用
- Jensen KS, Oskarsson T, Lähteenmäki PM, et al. Detection mode of childhood acute lymphoblastic leukaemia relapse and its effect on survival: a Nordic population-based cohort study. Br J Haematol. 2021. PMID: 34041748. doi:10.1111/bjh.17555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。